投资摘要
1. 针对遗传性视网膜营养不良的Luxturna(SPK-RPE65)已经提交FDA生物制剂上市许可申请,专家委员会时间安排在10月12号,FDA PDUFA 日期是2018年1月12号。基于现有的数据,我们认为专家委员会有80%以上几率会取得正...查看全文
智通财经APP获悉,近期,RBC针对Verrica Pharmaceuticals(VRCA.US)、Sangamo Therapeutics(SGMO.US)、GooseHead Insurance(GSHD.US)三家公司发表研报,并强调了这三只股票未来强劲的长期增长前景,预计在未来一年的上行空间将至少达到50... 网页链接
$Sangamo Therapeutics(SGMO)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001628280-24-022194 Act: 34 Size: 7 MB 网页链接
$Sangamo Therapeutics(SGMO)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001628280-24-022186 Act: 34 Size: 329 KB 网页链接
$Sangamo Therapeutics(SGMO)$ 8-K Current report, item 3.01 Accession Number: 0001628280-24-019337 Act: 34 Size: 184 KB 网页链接
$Sangamo Therapeutics(SGMO)$ ARS Annual Report to Security Holders Accession Number: 0001193125-24-102893 Act: 34 Size: 17 MB 网页链接
$Sangamo Therapeutics(SGMO)$ DEF 14A Other definitive proxy statements Accession Number: 0001628280-24-016932 Act: 34 Size: 17 MB 网页链接
$Sangamo Therapeutics(SGMO)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000814133-24-000068 Act: 34 Size: 4 KB 网页链接
$Sangamo Therapeutics(SGMO)$ PRE 14A Other preliminary proxy statements Accession Number: 0001628280-24-014660 Act: 34 Size: 17 MB 网页链接
$Sangamo Therapeutics(SGMO)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001193125-24-076613 Act: 34 Size: 915 KB 网页链接
$Sangamo Therapeutics(SGMO)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001193125-24-076462 Act: 33 Size: 3 MB 网页链接
$Sangamo Therapeutics(SGMO)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001628280-24-010790 Act: 34 Size: 360 KB 网页链接